Perspectives

April 26, 2024 Better Together: Alnylam and Organized Customer Health Systems Want to Improve Access and ... Alnylam's Head of Strategic Accounts discusses the rise of the Integrated Delivery Network and manufacturer relationship Read More ›
April 2, 2024 2023 Year in Review: CEO Yvonne Greenstreet Reflects on a Year of Substantial Growth and P ... Alnylam CEO Yvonne Greenstreet reflects on the company's accomplishments in 2023 and highlights of the 2023 annual report. Read More ›
April 24, 2023 2022 Annual Report: CEO Yvonne Greenstreet Reflects on the Next Chapter in the RNAi Revolu ... Alnylam CEO Yvonne Greenstreet reflects on the company's accomplishments in 2022 and highlights of the 2022 annual report. Read More ›
October 24, 2022 “Be the Link!” Learn from patients on World Amyloidosis Day No one knows this better than Jean-Christophe Fidalgo, President of the Amyloidosis Alliance, who has been living with hATTR amyloidosis for more than 20 years. Read More ›
May 13, 2022 Hypertension: Charting A New Course to Address a Public Health Challenge Hypertension (high blood pressure) has seen limited medical innovation in recent history and remains a serious public health issue... Read More ›
April 15, 2022 2021 Annual Report: CEO Yvonne Greenstreet Reflects on an Important Year in the RNAi Revol ... In conjunction with the publishing of Alnylam's 2021 Annual Report, Alnylam's CEO Yvonne Greenstreet reflects on the year that was... Read More ›
October 1, 2020 A New European Biotech Social Pact The European Pact builds on Alnylam’s own pledge, encouraging biotech companies to be a force for good in partnering with European authorities, citizens and... Read More ›
September 10, 2020 Brendan Martin on the Pharmaphorum Podcast Alnylam’s Brendan Martin, Head of Europe, Middle East, Africa, and Canada and General Manager for the UK & Ireland, recently spoke on the Pharmaphorum podcast. Read More ›
September 2, 2020 With Innovation in Market Access, European Patients Can Fully Experience Biotech’s Transfo ... What’s needed is a larger measure of creativity, flexibility and coordination around market access. This must become the new baseline environment in which... Read More ›
April 11, 2019 Letter to the Editor: Federal Research is Important, but Companies Turn it Into Actual Tre ... John Maraganore wrote a Letter to the Editor in The Washington Post about the importance of federal research... Read More ›

Get In Touch

Have any questions or comments about the content you see on this page?

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site